Management of Hepatic Encephalopathy

Introduction to Hepatic Encephalopathy Management

The American Association for the Study of Liver Diseases recommends that all patients with hepatic encephalopathy should receive immediate treatment with lactulose as first-line therapy while simultaneously identifying and correcting precipitating factors, which alone resolves approximately 90% of cases 1, 2
The management follows a structured four-pronged approach, including initiating basic care, excluding alternative causes of altered mental status, identifying and correcting precipitating factors, and beginning empirical lactulose therapy 1

Patients with grades 0-2 hepatic encephalopathy should be managed on a general medicine ward with frequent mental status monitoring, and transferred to ICU if consciousness deteriorates 3
Immediate ICU admission is mandatory for patients with grades 3-4 hepatic encephalopathy who are unable to protect their airway, as they are at high risk for aspiration and require intensive monitoring 2

Lactulose 25 mL orally every 12 hours, titrated to achieve 2-3 soft bowel movements per day, is the recommended first-line treatment for hepatic encephalopathy, and can be administered via nasogastric tube in patients unable to swallow or at aspiration risk 2, 1
Rifaximin 550 mg orally twice daily should be added to lactulose for secondary prophylaxis after more than one additional episode of overt hepatic encephalopathy within 6 months, as it reduces recurrence risk by 58% 2

After the first episode of overt hepatic encephalopathy, lactulose should be continued indefinitely as secondary prophylaxis, and rifaximin should be added after recurrent episodes despite lactulose therapy 2, 5
The first episode of overt hepatic encephalopathy should prompt referral to a transplant center for evaluation, as liver transplantation represents the definitive treatment for hepatic encephalopathy 2, 3

Plasma ammonia levels should be measured in suspected cases of hepatic encephalopathy, but should not be relied upon exclusively for diagnosis or monitoring 5, 4
Proton pump inhibitors, benzodiazepines, and all sedatives should be avoided in patients with hepatic encephalopathy due to increased risk of worsening encephalopathy or other adverse effects 4, 3